BillionToOne Inc. Class A (BLLN)
NASDAQ: BLLNHealth CareMedical SpecialitiesUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
BLLN stock chart
Technical analysisKey statistics
All statistics- Market cap
- $4.52B
- P/E (TTM)
- 151.98
- Forward P/E
- 64.48
- EPS (TTM)
- $0.63
- Dividend yield
- None
- 52-week range
- 61.96 – 150.44
- Day range
- 94.52 – 99.60
- Volume / Avg
- 679.80K / 696.69K
- Beta
- —
- Shares outstanding
- 42.64M
52-week range
BLLN stock today
Shares of BillionToOne (BLLN) finished lower on Oct 7 at $95.75, a drop of 4.19% or $4.19 per share, versus the S&P 500's 0.22% decline. At this level, BLLN sits in the middle of its 52-week range of $61.96 to $150.44: 36.4% below the high, set on Aug 5, 2026 and 54.5% above the low. BLLN is up 17.0% year to date, outperforming the S&P 500 (+14.0%).
At 152.0x trailing earnings, BillionToOne trades above the peer-group median of 30.3x. Its forward P/E of 64.5x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.
Summary generated from market data by MetaCap's automated system. Methodology
About BillionToOne
Company profileBillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection. It also offers UNITY Complete, a non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw; Northstar Select, a liquid biopsy test that provides a list of mutations that are present in the tumor and types of mutations detected that include deletions, insertions, and point mutations; and Northstar Response, a methylation-based assay that quantifies the amount of cancer at the single molecule level without requiring a tissue biopsy, enabling real-time monitoring of patient response to therapy with unprecedented precision.
- Sector
- Health Care
- Industry
- Medical Specialities
- CEO
- Dr. Oguzhan Atay Ph.D.
- Headquarters
- Menlo Park, CA
- Employees
- 713
- IPO year
- 2025
- Website
- billiontoone.com
Financial highlights
Full financialsIn fiscal 2025, BillionToOne generated $305.1 million in revenue, up 100.0% from fiscal 2024, its 2nd consecutive year of revenue growth. Net income was $7.5 million, for a net margin of 2.4% versus a median of -71.3% in the prior 2 years. Gross margin was 68.3% (up from 53.0%) and operating margin 5.3%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Revenue | $305.11M | $152.58M | $71.73M |
| Growth | +99.97% | +112.72% | — |
| Net income | $7.45M | $-41.57M | $-82.68M |
| EPS (diluted) | $0.14 | $-4.12 | $-8.45 |
Analyst forecast
ForecastConsensus (8 analysts)
strong_buy
Avg. price target
$129.00+34.73%
- Strong buy 2
- Buy 5
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Q2 2026)
- Aug 5, 2026
- EPS actual vs est.
- $0.15 vs —
BillionToOne peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| CONConcentra Group Holdings Parent Inc. | 36.40 | 0.00% | $4.64B | vs BLLN |
| RDNTRadNet Inc. | 68.61 | -2.38% | $5.40B | vs BLLN |
| VCYTVeracyte Inc. | 43.16 | -3.34% | $3.47B | vs BLLN |
| CDNACareDx Inc. | 63.04 | -1.18% | $3.26B | vs BLLN |
| CELCCelcuity Inc. | 65.78 | -7.68% | $3.22B | vs BLLN |
| GRALGRAIL Inc. | 132.90 | -3.19% | $5.94B | vs BLLN |
| ACHCAcadia Healthcare Company Inc. | 29.23 | +0.65% | $2.72B | vs BLLN |
| CLOVClover Health Investments Corp. Class A | 4.56 | -0.87% | $2.42B | vs BLLN |
Indexes, lists and sector
BillionToOne stock FAQ
What is BillionToOne's stock price today?
BLLN last traded at $95.75 as of Oct 7, 4:00 PM EDT, down 4.19% on the day. Prices are delayed at least 15 minutes.
What is BLLN's P/E ratio?
BLLN trades at a trailing P/E ratio of 151.98 and a forward P/E of 64.48, compared with a median of 30.3 for its closest peers.
Who is BillionToOne's CEO?
Dr. Oguzhan Atay Ph.D. is the chief executive officer of BillionToOne Inc. Class A, which has about 713 employees.
What is the BLLN 52-week high?
The 52-week high for BLLN is $150.44 and the 52-week low is $61.96. The stock is currently 36.4% below its high.